Company intelligence / Profile preview
Kalbio Global Medika
Bekasi, West Java, Indonesiakalbio.co.id ↗
- Ownership
- Private
- Employees
- ~291
- Development stage
- Commercial
01
Overview
KGM has achieved commercial approval for at least one biosimilar/novel biologic in Indonesia and provides contract manufacturing services for preclinical to commercial supply. The company’s pipeline includes several biosimilars and novel biologics, with a focus on markets outside the US, Canada, Western Europe, and China. It was the first organization in Indonesia approved for production of commercial biotherapeutics.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Monoclonal antibodyProteinRecombinant proteinBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Gan & Lee PharmaceuticalsKGbio/Kalbe Genexine Biologics Group
Beyond the preview
Go deeper on Kalbio Global Medika.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kalbio Global Medika.